Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Liver energy metabolism reprogramming: GLP-1RA reduces hepatic glucose output by decreasing hepatic FFA uptake and the expression of key gluconeogenesis enzymes such as PEPCK and G6Pase, while promoting liver sensitivity to insulin, transforming the liver from an "energy output organ" to an "energy storage organ"
The FDAs greenlight was supported by data from the Phase III MANDARA trial, which set Fasenra against GSKs Nucala, previously the only approved treatment for EGPA
Age-related macular degeneration
Modified from Ravassa et al
US$ 20.43
US$ 23.02
US$ 26.40
US$ 26.87
